The effect of lidocaine spray in reducing ophthalmic neuralgia in patients with multiple sclerosis
Phase 2
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20231029059896N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Definite MS confirmed by MRI
Confirmation of ophthalmic neuralgia without response to drug treatment
Performing a lidocaine sensitivity test and proving the absence of lidocaine sensitivity
The patient's willingness to participate in the study and obtain informed consent
The patient's MS must be of the relapsing remitting type and must have been approved by a neurologist.
Exclusion Criteria
Occurrence of drug side effects
Worsening of symptoms.
Patient dissatisfaction
More than three months have passed since the diagnosis of their disease and they have entered the chronic phase
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of the patient's pain intensity based on Visual Analogue Scale (VAS) criteria. Timepoint: Before using the spray. Method of measurement: These outcomes are measured by a neurologist based on the VAS.
- Secondary Outcome Measures
Name Time Method Measurement of pain-free time after each use of the spray?. Timepoint: The pain-free period after using the spray during pain is recorded in 0-6-12-24 hours and more than one week from the patients. Method of measurement: These outcomes are measured by the evaluator, who is a final year medical student who is not aware of the assignment of the subjects to each of the two allocation groups and the drugs used. Pain-free time after using the spray during pain in hours 0-6-12-24 and more than one week of patients are recorded. The instrument for measuring this variable is based on the patient's statements and its unit is amount of hours.